- RecruitingPHASE3
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
This study looks at a new drug called taletrectinib for people with a type of lung cancer (NSCLC) that has a specific gene change (ROS1 positive). It aims to see if the drug can stop the cancer from coming back after surgery.
For: Non-small Cell Lung Cancer (NSCLC)United States · Canada · China - Active not recruitingPHASE2
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
This study is testing a new drug, taletrectinib, for people with a specific type of lung cancer called ROS1-positive non-small cell lung cancer. Researchers want to see how safe and effective this medication is. It's for patients whose cancer has spread or is difficult to treat.
For: Non Small Cell Lung CancerUnited States · Canada · China